San Diego-based Accriva Diagnostics, a maker of point-of-care tests for strokes and other cardiovascular conditions, just raised about $15.5 million in equity, according to a regulatory filing.
It’s got a number of products – an anticoagulation monitoring system called Hemochron, a test that measures a patient’s platelet reactivity to antiplatelet meds, a heelstick device for newborns and several others. One of its devices, the InRhythm, isn’t yet FDA approved – the rest are.
Previous investors include Warburg Pincus, Bay City Capital and Kleiner Perkins Caufield and Byers. Last year, it raised about $55 million. It’s always interesting when you see larger, more established life sciences companies continue to raise equity – the first incarnation of Accriva was founded in 1969.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Accriva was formed in 2013 after a merger between ITC Nexus and Accumetrics. Early last year, Accriva brought on a new CEO – Scott Cramer – to help ease the integration.
